Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

NCT02937818 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02937818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02937818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2016
Completion date
November 27, 2023
Enrollment
72 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

platinum refractory extensive-stage small cell lung carcinoma